Kimberly-Clark to Acquire Kenvue
Kimberly-Clark has announced its plan to purchase Kenvue, the maker of Tylenol, in a cash and stock acquisition valued at approximately $48.7 billion.
Upon completion, Kimberly-Clark shareholders will own about 54% of the combined company, while Kenvue shareholders will hold 46%.
The Big Picture
The merger brings together a broad array of popular consumer brands, including Kenvue’s Tylenol, Listerine, and Band-Aid alongside Kimberly-Clark’s Cottonelle, Huggies, and Kleenex.
Key Details
- The takeover ranks among the largest corporate deals announced in 2025.
“We will serve billions of consumers across every stage of life.” - Mike Hsu, Kimberly-Clark Chairman and CEO
Leadership and Next Steps
Mike Hsu will lead as chairman and CEO of the merged company, and three Kenvue board members will join Kimberly-Clark’s board upon closing.
Author summary: Kimberly-Clark buys Kenvue for $48.7 billion.